| A19 | Subtype D HIV-1 reservoir levels and viral sequence profiles in Rakai, Uganda | E-poster | Characterizing HIV/SIV reservoirs and rebounding virus |
| D20 | Successful implementation of telemedicine and pharmacy enhanced HIV services as response to COVID-19 quarantine among health insured patients in Argentina | On-demand oral abstract session | Adaptations of HIV treatment services during COVID-19 |
| D20 | Successful scale-up of optimal antiretroviral regimens and improvement in viral suppression for children and adolescents living with HIV amidst COVID-19 pandemic in Kenya | E-poster | Adaptations of HIV treatment services during COVID-19 |
| B35 | Successfully (and safely) enrolling a multi-center HIV antiretroviral clinical trial during the COVID-19 pandemic: lessons learned from Kenya | E-poster | Regimen simplification and switch studies |
| D84 | Sustaining the key population contacts during COVID 19 pandemic in Delhi | E-poster | Sex workers |
| B35 | Switch to BIC/FTC/TAF in virally suppressed PLWH: efficacy and tolerability | E-poster | Regimen simplification and switch studies |
| B24 | Switch to INSTI more than offset negative effects of weight gain on incidence of insulin resistance in people living with HIV | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B35 | Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial | E-poster | Regimen simplification and switch studies |
| B35 | Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA) | Oral abstract session with live Q&A | Regimen simplification and switch studies |
| C37 | Syphilis among key population in Indonesia: 25 years of STI control program | E-poster | STI diagnosis, treatment and prevention |